Company profile: Creative Medical Technology
1.1 - Company Overview
Company description
- Provider of regenerative and cell therapy platforms in immunology, urology, neurology, and orthopedics, including ImmCelzTM autologous immune cell therapy; Enhanced Allogenic Platform using perinatal tissue cells; Supercharged Autologous Immunotherapy; Reprogrammed Cell Therapy with iPSCs; Rapid Autologous Therapies, and CaverStem for erectile dysfunction.
Products and services
- Enhanced Allogenic Platform: A clinical-grade cell therapy platform using perinatal derived tissue cells to treat immune, endocrine, and other disorders through allogeneic cell-based interventions
- ImmCelzTM: A patient-specific regenerative medicine platform using autologous immune cells sourced from the individual to treat various conditions via personalized autologous cell therapy
- Reprogrammed Cell Therapy Platform: A scalable platform that reprograms adult cells into induced pluripotent stem cells (iPSCs), which can then be differentiated into any human cell type
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Creative Medical Technology
OvaScience
HQ: United States
Website
- Description: Provider of life sciences solutions focused on the discovery, development and commercialization of treatments for infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OvaScience company profile →
StemVax Therapeutics
HQ: United States
Website
- Description: Provider of novel immunotherapies for brain tumor patients, developing immunotherapeutic approaches to treat Glioblastoma Multiforme.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full StemVax Therapeutics company profile →
BioSenic
HQ: Belgium
Website
- Description: Provider of biopharmaceutical and cell therapy products for bone and osteo-articular diseases, offering ALLOB for bone regeneration; JTA-004 for knee osteoarthritis pain; ArsciCor, an oral arsenic trioxide formulation for chronic graft versus host disease; and ArsciMed, an intravenous arsenic trioxide treatment for autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioSenic company profile →
Sana
HQ: United States
Website
- Description: Provider of engineered cell medicines, offering in vivo and ex vivo cell engineering platforms and hypoimmune allogeneic CAR T therapies using modified healthy donor T cells to evade immune rejection. Pipeline includes SC291 (CD19) for B-cell malignancies and severe B-cell autoimmune diseases, and SC262 (CD22) for B-cell malignancies, all in Phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sana company profile →
Ossium Health
HQ: United States
Website
- Description: Provider of a bank of cryopreserved bone marrow from deceased donors for cell therapies targeting hematologic diseases, including blood cancers, organ transplant rejection, and musculoskeletal defects; offering OssiGraft, a cryopreserved viable bone matrix allograft. Offers GMP human mesenchymal stem cells and selected CD34+ cells from vertebral bodies, plus research-use MSCs and CD34+ cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ossium Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Creative Medical Technology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Creative Medical Technology
2.2 - Growth funds investing in similar companies to Creative Medical Technology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Creative Medical Technology
4.2 - Public trading comparable groups for Creative Medical Technology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →